Pharmaceutical

Bio Usawa Biotechnology and ServareGMP Form Strategic Partnership to Advance Accessible Biotherapeutic Manufacturing in Africa

Strategic alliance brings advanced first-of-its-kind biotherapeutic production, workforce training, and rapid response capabilities to low- and middle-income countries to address…

5 months ago

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal…

5 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

WALTHAM, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D.,…

5 months ago

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics…

5 months ago

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm…

5 months ago

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

The trial will evaluate safety, dosing, and efficacy in patients with cardiogenic shock Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4…

5 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

The Company added Congresswoman Cathy McMorris Rodgers & Ajay Raju, Esq. to the Board of Directors.Philadelphia, Pennsylvania--(Newsfile Corp. - July…

5 months ago

Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology

Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030…

5 months ago

Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology

Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030…

5 months ago